within Pharmacolibrary.Drugs.ATC.N;

model N05BA23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.96,
    Cl             = 4.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.044,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Tofisopam is a 2,3-benzodiazepine derivative with anxiolytic properties but distinct from classical 1,4- and 1,5-benzodiazepines. It is primarily used for the treatment of anxiety and psychosomatic disorders and has little sedative, muscle relaxant, or anticonvulsant effects. Tofisopam is not widely approved, but is or was available in some European and Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Drabant, S, et al., &amp; Klebovich, I (2006). Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. <i>European journal of clinical pharmacology</i> 62(7) 587–588. DOI:<a href=&quot;https://doi.org/10.1007/s00228-006-0160-9&quot;>10.1007/s00228-006-0160-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16791582/&quot;>https://pubmed.ncbi.nlm.nih.gov/16791582</a></p></li><li><p>Tomori, E, et al., &amp; Horváth, G (1984). Investigation of metabolites of tofizopam in man and animals. <i>Polish journal of pharmacology and pharmacy</i> 36(4) 423–430. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6152052/&quot;>https://pubmed.ncbi.nlm.nih.gov/6152052</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BA23;
